Pascal Touchon
Chief Executive Officer at ATARA BIOTHERAPEUTICS, INC.
Net worth: 1 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric Hyllengren | M | - | 6 years | |
| Richard A. Markus | M | - |
Dantari, Inc.
 Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
| Carol Gallagher | M | 59 | 11 years | |
| Margaret Liu | M | 66 | 7 years | |
| Marc M. P. de Garidel | M | 66 | 14 years | |
| Ameet Mallik | M | 51 | 3 years | |
| David Loew | M | 57 | 4 years | |
| Maria Grazia Roncarolo | M | 69 | 4 years | |
| Aymeric Le Chatelier | M | 55 | 10 years | |
| Piet Wigerinck | M | 58 | 6 years | |
| Michèle Ollier | M | 65 | 9 years | |
| Eric Dobmeier | M | 55 | 9 years | |
| William Heiden | M | 64 | 9 years | |
| Matthew Fust | M | 59 | 10 years | |
| Karen Witts | F | 61 | 2 years | |
| Noubar Afeyan | M | 60 |
Cogen Immune Medicine, Inc.
 Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | - |
| Jose-Carlos Gutiérrez-Ramos | M | 61 |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | 6 years |
| Philippe Lopes-Fernandes | M | - | 4 years | |
| Laetitia Ducroquet | F | 44 | 4 years | |
| Catherine Abi-Habib | F | - | 2 years | |
| Aidan Murphy | M | 58 | 6 years | |
| Gina Knox | F | - |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
| Naomi Binoche | F | - | - | |
| Christelle Huguet | M | 57 | 1 years | |
| Ioana Piscociu | F | - | - | |
| Dan Maziasz | M | - | 6 years | |
| Anna Mari Scheiffele | M | 50 | 3 years | |
| Regis Mulot | M | 58 | 6 years | |
| François-Maurice Garnier | M | 62 | 9 years | |
| Anhco Nguyen | M | 51 | 3 years | |
| David Berry | M | 47 |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | - |
| Sean E. Harper | M | 61 |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
| Mark E. Davis | M | - |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | 2 years |
| Carol Xueref | F | 67 | 12 years | |
| Craig Marks | M | - | - | |
| Antoine Flochel | M | 59 | 19 years | |
| Henri Beaufour | M | 59 | 19 years | |
| Gwenan White | F | - | 3 years | |
| Jill Henrich | F | - | - | |
| K. Murugan | M | 49 | 4 years | |
| Sandra Silvestri | M | 50 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mina Kim | F | 50 | 1 years | |
| Beth Seidenberg | M | 67 | 11 years | |
| Ronald Renaud | M | 55 | 2 years | |
| Roy Baynes | M | 69 | 4 years | |
| Joseph Newell | M | 54 | 5 years | |
| Christopher Haqq | M | 58 | 7 years | |
| Jakob Dupont | M | 58 | 3 years | |
| Kerry Beth Daly | F | - | - | |
| Derrell Porter | M | 53 | 2 years | |
| Utpal Koppikar | M | 53 | 5 years | |
| Manher AJ Joshi | M | - | 8 years | |
| Kristin Yarema | M | 53 | 2 years | |
| Joshua House | M | 43 | 3 years | |
| Amie Krause | F | - | 2 years | |
| Charlene Banard | F | 61 | 1 years | |
| House Joshua | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 59.65% |
| France | 23 | 40.35% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Pascal Touchon
- Personal Network
